A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology.
Michiko HamadaMichiharu HorikawaChie EnsakaMegumi EnomotoRena IshiiRena ToriumiNaoyuki TachibanaYuji TaketaniPublished in: Reproductive medicine and biology (2021)
An orally active GnRH Ant, relugolix, when used in controlled ovarian stimulation for ART, showed comparable clinical outcomes with cetrorelix.
Keyphrases